-transparent.png){kind=logo}
In a controlled trial including 80 patients suffering from different stages of rheumatoid arthritis it was demonstrated that D-penicillamine therapy favourably influences the clinical course of the disease as compared to a control group treated with antirheumatic drugs. Particularly the therapy continued over one year resulted in a significant fall of the joint and activity index as well as of the BSR. Side effects were observed in more than half of the cases. Renal, hematological and severe exanthematic complications forced to discontinue the administration of D-penicillamine in 6 of 41 cases. As compared to other therapeutics our study indicates that D-penicillamine and gold treatment are equivalent drugs in rheumatoid arthritis whereas immunosuppressive drugs are reserved for severe cases of rheumatoid arthritis because of their strong side effects.
H Warnatz, and
F Scheiffarth, and
W Gutmann
February 1977,
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
H Warnatz, and
F Scheiffarth, and
W Gutmann
December 1975,
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
H Warnatz, and
F Scheiffarth, and
W Gutmann
January 1969,
Verhandlungen der Deutschen Gesellschaft fur Rheumatologie,
H Warnatz, and
F Scheiffarth, and
W Gutmann
August 1980,
Klinische Wochenschrift,
H Warnatz, and
F Scheiffarth, and
W Gutmann
November 1977,
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
H Warnatz, and
F Scheiffarth, and
W Gutmann
August 1986,
Ryumachi. [Rheumatism],
H Warnatz, and
F Scheiffarth, and
W Gutmann
November 1973,
Munchener medizinische Wochenschrift (1950),
H Warnatz, and
F Scheiffarth, and
W Gutmann
January 1988,
Revmatologiia (Moscow, Russia),
H Warnatz, and
F Scheiffarth, and
W Gutmann
January 1979,
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
H Warnatz, and
F Scheiffarth, and
W Gutmann
March 1987,
Annals of the rheumatic diseases,
